Current Environment: Production

Medical Services

Specialties

Programs & Services

Education

Medical School

A.M. Dogliotti College of Medicine, University of Liberia

Monrovia, Liberia

Internship

John F. Kennedy Memorial Medical Center

Indio, CA

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

Boston, MA

Residency

The Royal Victoria Infirmary

Newcastle-upon-Tyne, England

Fellowship

Pediatric Hematology -Oncology

Boston Children's Hospital/Dana-Farber Cancer Institute

Boston, MA

Fellowship

Pathology

Harvard Medical School

Boston, MA

Professional History

Dr George received her MD from the University of Liberia and her PhD from the University of Newcastle-upon-Tyne, UK. She completed clinical training in pediatrics and hematology/oncology at the Royal Victoria Infirmary, Newcastle-upon-Tyne, Boston Childrens Hospital and DFCI, and post-doctoral research at Harvard Medical School and DFCI. Her laboratory focuses on identifying molecular targets in cancer cells that can be translated into novel therapies with special emphasis on the pediatric solid tumor neuroblastoma. The translational research program in her laboratory integrates cancer biology, preclinical drug development and clinical trials targeting molecular aberrations in neuroblastoma and other pediatric solid tumors.

Publications

  1. A drug that induces the microRNA miR-124 enables differentiation of retinoic acid-resistant neuroblastoma cells. Sci Signal. 2025 Apr 15; 18(882):eads2641. View Abstract

  2. Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology. NPJ Precis Oncol. 2024 Nov 08; 8(1):255. View Abstract

  3. Novel miRNA-inducing drugs enable differentiation of retinoic acid-resistant neuroblastoma cells. bioRxiv. 2024 Jul 29. View Abstract

  4. Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation. Cell Rep. 2024 05 28; 43(5):114165. View Abstract

  5. The MYCN 5' UTR as a therapeutic target in neuroblastoma. Cell Rep. 2024 05 28; 43(5):114134. View Abstract

  6. CKLF instigates a "cold" microenvironment to promote MYCN-mediated tumor aggressiveness. Sci Adv. 2024 Mar 15; 10(11):eadh9547. View Abstract

  7. Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch. J Immunother Cancer. 2022 12; 10(12). View Abstract

  8. Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Nat Cancer. 2022 10; 3(10):1228-1246. View Abstract

  9. Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Front Oncol. 2021; 11:773186. View Abstract

  10. Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration. Cell Rep. 2021 07 13; 36(2):109363. View Abstract

  11. Giotto: a toolbox for integrative analysis and visualization of spatial expression data. Genome Biol. 2021 03 08; 22(1):78. View Abstract

  12. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Eur J Cancer. 2020 09; 136:52-68. View Abstract

  13. Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras. Cell Stem Cell. 2020 04 02; 26(4):579-592.e6. View Abstract

  14. MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nat Commun. 2020 02 14; 11(1):913. View Abstract

  15. Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. Nat Commun. 2019 12 20; 10(1):5806. View Abstract

  16. Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma. J Clin Invest. 2019 10 01; 129(10):4377-4392. View Abstract

  17. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. Nature. 2019 08; 572(7771):676-680. View Abstract

  18. JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. Nat Commun. 2019 07 25; 10(1):3319. View Abstract

  19. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat Commun. 2019 04 15; 10(1):1757. View Abstract

  20. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature. 2018 09; 561(7724):556-560. View Abstract

  21. Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). J Med Chem. 2018 05 10; 61(9):4249-4255. View Abstract

  22. Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. Cell Chem Biol. 2018 02 15; 25(2):135-142.e5. View Abstract

  23. Super-Enhancer-Driven Transcriptional Dependencies in Cancer. Trends Cancer. 2017 04; 3(4):269-281. View Abstract

  24. Cbx3/HP1? deficiency confers enhanced tumor-killing capacity on CD8+ T cells. Sci Rep. 2017 02 21; 7:42888. View Abstract

  25. Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. Mol Oncol. 2016 06; 10(6):866-78. View Abstract

  26. Targeting ALK: The Ten Lives of a Tumor. Cancer Discov. 2016 Jan; 6(1):20-1. View Abstract

  27. Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. J Med Chem. 2015 Dec 10; 58(23):9296-9308. View Abstract

  28. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet. 2015 Dec; 47(12):1411-4. View Abstract

  29. Seek and Ye Shall Find: Subclonal Anaplastic Lymphoma Kinase Mutations. Clin Cancer Res. 2015 Nov 01; 21(21):4747-9. View Abstract

  30. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. 2015 Oct; 64(10):1251-60. View Abstract

  31. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014 Dec 08; 26(6):909-922. View Abstract

  32. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014 Nov 20; 159(5):1126-1139. View Abstract

  33. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget. 2014 Sep 30; 5(18):8737-49. View Abstract

  34. Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. PLoS One. 2014; 9(3):e92886. View Abstract

  35. Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models. PLoS Genet. 2013 Jun; 9(6):e1003533. View Abstract

  36. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 2012 Jul 10; 22(1):117-30. View Abstract

  37. Promising therapeutic targets in neuroblastoma. Clin Cancer Res. 2012 May 15; 18(10):2740-53. View Abstract

  38. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012 Mar 20; 21(3):362-73. View Abstract

  39. Tumor histology during induction therapy in patients with high-risk neuroblastoma. Pediatr Blood Cancer. 2012 Sep; 59(3):506-10. View Abstract

  40. Emerging importance of ALK in neuroblastoma. Semin Cancer Biol. 2011 Oct; 21(4):267-75. View Abstract

  41. Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. ACS Med Chem Lett. 2011 May 12; 2(5):379-384. View Abstract

  42. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer. 2010 Oct 15; 9:277. View Abstract

  43. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Oct; 55(4):629-38. View Abstract

  44. Pharmacotherapy of neuroblastoma. Expert Opin Pharmacother. 2010 Jun; 11(9):1467-78. View Abstract

  45. Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res. 2009 May 15; 69(10):4143-9. View Abstract

  46. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009 Mar; 9(3):331-56. View Abstract

  47. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16; 455(7215):975-8. View Abstract

  48. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008 Apr 01; 22(7):884-93. View Abstract

  49. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res. 2007 Dec 01; 67(23):11234-43. View Abstract

  50. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One. 2007 Feb 28; 2(2):e255. View Abstract

  51. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. Clin Cancer Res. 2006 Oct 01; 12(19):5693-7. View Abstract

  52. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006 Jun 20; 24(18):2891-6. View Abstract

  53. Zebrafish foxd3 is selectively required for neural crest specification, migration and survival. Dev Biol. 2006 Apr 01; 292(1):174-88. View Abstract

  54. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005 Sep 20; 23(27):6466-73. View Abstract

  55. Association between congenital cardiovascular malformations and neuroblastoma. J Pediatr. 2004 Apr; 144(4):444-8. View Abstract

  56. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res. 2003 Aug 15; 9(9):3338-44. View Abstract
BESbswy